Trinity Biotech (NASDAQ:TRIB) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIBGet Rating) in a research note issued to investors on Friday. The firm set a “buy” rating on the stock.

NASDAQ:TRIB opened at $1.15 on Friday. The stock has a market cap of $24.04 million, a price-to-earnings ratio of 12.78 and a beta of 1.33. The company’s 50 day moving average price is $1.09 and its 200-day moving average price is $1.37. Trinity Biotech has a 52 week low of $0.86 and a 52 week high of $3.98.

Trinity Biotech (NASDAQ:TRIBGet Rating) last issued its quarterly earnings data on Monday, April 11th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.13). Trinity Biotech had a net margin of 0.94% and a negative return on equity of 27,745.46%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hunter Associates Investment Management LLC raised its position in Trinity Biotech by 2.0% in the third quarter. Hunter Associates Investment Management LLC now owns 2,095,900 shares of the company’s stock worth $4,527,000 after acquiring an additional 40,200 shares during the period. Wealthsource Partners LLC bought a new position in Trinity Biotech in the third quarter worth approximately $65,000. LPL Financial LLC increased its stake in shares of Trinity Biotech by 48.3% in the third quarter. LPL Financial LLC now owns 89,073 shares of the company’s stock worth $192,000 after purchasing an additional 29,000 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Trinity Biotech in the third quarter worth $139,000. Finally, Morgan Stanley increased its stake in shares of Trinity Biotech by 40.0% in the third quarter. Morgan Stanley now owns 20,765 shares of the company’s stock worth $45,000 after purchasing an additional 5,932 shares in the last quarter. Institutional investors and hedge funds own 25.79% of the company’s stock.

Trinity Biotech Company Profile (Get Rating)

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Featured Articles

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.